Skip to main content

Research Repository

Advanced Search

All Outputs (4)

Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-light vitiligo three-arm RCT (2020)
Journal Article
Batchelor, J. M., Thomas, K. S., Akram, P., Azad, J., Bewley, A., Chalmers, J. R., …Montgomery, A. A. (2020). Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-light vitiligo three-arm RCT. Health Technology Assessment, 24(64), 1-164. https://doi.org/10.3310/hta24640

Background: Systematic reviews suggest that narrowband ultraviolet B light combined with treatments such as topical corticosteroids may be more effective than monotherapy for vitiligo. Objective: To explore the clinical effectiveness and cost-effecti... Read More about Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-light vitiligo three-arm RCT.

An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the HI-Light Vitiligo Trial)* (2020)
Journal Article
Sach, T., Thomas, K., Batchelor, J., Akram, P., Chalmers, J., Haines, R., …The UK Dermatology Clinical Trials Network’s HI‐LIGHT Vitiligo Trial Team. (2021). An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the HI-Light Vitiligo Trial)*. British Journal of Dermatology, 184(5), 840-848. https://doi.org/10.1111/bjd.19554

Background: Economic evidence for vitiligo treatments is absent. Objectives: To determine the cost-effectiveness of (i) handheld narrowband ultraviolet B (NB-UVB) and (ii) a combination of topical corticosteroid (TCS) and NB-UVB compared with TCS alo... Read More about An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the HI-Light Vitiligo Trial)*.

Randomised controlled trial of topical corticosteroid and home?based narrowband UVB for active and limited vitiligo: results of the HI?Light Vitiligo trial (2020)
Journal Article
Thomas, K., Batchelor, J. M., Akram, P., Chalmers, J. R., Haines, R., Meakin, G. D., …Montgomery, A. A. (2021). Randomised controlled trial of topical corticosteroid and home‐based narrowband UVB for active and limited vitiligo: results of the HI‐Light Vitiligo trial. British Journal of Dermatology, 184(5), 828-839. https://doi.org/10.1111/bjd.19592

Background Evidence for the effectiveness of vitiligo treatments is limited. Objectives To determine effectiveness of (a) hand‐held narrowband‐UVB (NB‐UVB) and (b) combination of potent topical corticosteroid (TCS) and NB‐UVB compared to TCS, fo... Read More about Randomised controlled trial of topical corticosteroid and home?based narrowband UVB for active and limited vitiligo: results of the HI?Light Vitiligo trial.

Protocol for a multi-centre randomised controlled stand-alone feasibility trial to assess potential effectiveness and cost-effectiveness of digital hearing aids in patients with tinnitus and hearing loss (the HUSH trial) (2020)
Journal Article
Haines, R., White, J., Meakin, G., Tan, W., Hepburn, T., Leighton, P., …Sereda, M. (2020). Protocol for a multi-centre randomised controlled stand-alone feasibility trial to assess potential effectiveness and cost-effectiveness of digital hearing aids in patients with tinnitus and hearing loss (the HUSH trial). Pilot and Feasibility Studies, 6, Article 41. https://doi.org/10.1186/s40814-020-00582-5

Background: The most common management strategy for tinnitus provided in UK audiology clinics is education and advice. This may also be combined with some form of sound therapy (e.g. digital hearing aids). While education and advice is generally prov... Read More about Protocol for a multi-centre randomised controlled stand-alone feasibility trial to assess potential effectiveness and cost-effectiveness of digital hearing aids in patients with tinnitus and hearing loss (the HUSH trial).